This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Incyte (INCY) Announces Positive Results on Jakafi for GVHD
by Zacks Equity Research
Incyte (INCY) reports positive results on Jakafi from the REACH trial for the indication of acute GVHD. The company plans to file a sNDA for the drug in the third quarter.
Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive
by Zacks Equity Research
AbbVie (ABBV) announces positive top-line results from the fifth phase III study on its JAK inhibitor, upadacitinib in moderate-to-severe rheumatoid arthritis.
Eli Lilly's Olumiant Gets FDA Nod for Rheumatoid Arthritis
by Zacks Equity Research
Eli Lilly (LLY) and its partner Incyte announce approval of their arthritis drug, Olumiant, in the United States. The drug will be available at two-fifth of the price of leading RA drugs.
Incyte (INCY) Up 10.2% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Incyte (INCY) Incurs Loss in Q1, Revenues Miss Estimates
by Zacks Equity Research
Incyte (INCY) reported disappointing results for the first quarter wherein the company reported a loss against expectation of earnings and sales too missed estimates.
Incyte (INCY) Reports A Loss in Q1
by Ekta Bagri
Incyte reported a loss in the first quarter while sales also beat estimates.
Should You Sell Incyte (INCY) Before Earnings?
by Zacks Equity Research
Incyte (INCY) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
Can Jafaki Help Incyte (INCY) Beat Earnings Estimates in Q1?
by Zacks Equity Research
Incyte (INCY) is likely to beat on earnings when it reports first-quarter results on May 1 driven by strong Jakafi sales.
Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales
by Zacks Equity Research
The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.
Lilly (LLY) Tops on Q1 Earnings, Raises '18 View, Stock Up
by Zacks Equity Research
Eli Lilly (LLY) beats estimates for both earnings and sales in Q1 and raises guidance for 2018. Shares rise in pre-market trading.
Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Lilly's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis
by Zacks Equity Research
The biotech sector was in the news last week as shares of Spectrum surged on positive data from a phase II study while Incyte plunged on the failure of melanoma study.
NewLink Shares Plunge After Incyte & Merck's Study Fails
by Zacks Equity Research
Shares of NewLink Genetics Corp. (NLNT) plunged about 42.6% following the news of the failure of Incyte and Merck's phase III combination study for metastatic melanoma.
Incyte's Epacadostat Fails in Melanoma Study, Shares Plunge
by Zacks Equity Research
Incyte's (INCY) epacadostat in combination with Merck's Keytruda fails to meet primary endpoint of PFS in a phase III melanoma study.
Incyte (INCY) Up 5.2% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AstraZeneca's Final Data From Key Lung Cancer Study Delayed
by Zacks Equity Research
AstraZeneca's (AZN) final overall survival data from the pivotal phase III MYSTIC study on Imfinzi in first line lung cancer to be delayed in the second half of 2018.
The Zacks Analyst Blog Highlights: Royal Dutch, Mastercard, Itau Unibanco, Suncor and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Royal Dutch, Mastercard, Itau Unibanco, Suncor and Incyte
Zacks.com featured highlights include: Incyte, Altice USA, Archrock, Live Nation and PTC
by Zacks Equity Research
Zacks.com featured highlights include: Incyte, Altice USA, Archrock, Live Nation and PTC
Get Rid of 5 Toxic Stocks or Sell Short for Profit
by Zacks Equity Research
Overblown toxic stocks are generally susceptible to outside shocks and are loaded with a huge amount of debt.
Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales
by Zacks Equity Research
Incyte (INCY) beat on revenues in the fourth quarter driven by an increase in Jakafi sales. The guidance for 2018 was also encouraging.
Incyte (INCY) Beats on Sales in Q4
by Ekta Bagri
Incyte (INCY) beat on sales in the fourth quarter driven by growth in Jakafi sales.
Why Incyte (INCY) Might Surprise This Earnings Season
by Zacks Equity Research
Incyte (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?
by Zacks Equity Research
Growth in Jakafi sales are likely to help Incyte (INCY) to beat on earnings in Q4.
Will Prothena (PRTA) Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
Although Prothena's (PRTA) track record is good, the company is unlikely to beat estimates in the current quarter given the unfavorable rank and Earnings ESP.